| Indication |
Phase |
Sample Size |
Study Design |
| Acne Vulgaris |
2 |
100 |
Randomized,
double-blind, multi-center, placebo-controlled, parallel-group,
proof of concept study |
| Atopic Dermatitis |
3 |
350 |
Randomized,
double-blind, placebo-controlled, parallel group study |
| Atopic Dermatitis |
2 |
200 |
Open-label, treatment
continuation study |
| Atopic Dermatitis |
2 |
150 |
Open-label, treatment
continuation study |
| Atopic Dermatitis |
2 |
200 |
Multi-center,
randomized, double-blind, placebo-controlled, parallel group
study |
| Atopic Dermatitis |
2 |
40 |
Open-label study |
| Atopic Dermatitis |
2 |
60 |
Multi-center,
randomized, controlled, double-blind study |
| Plaque Psoriasis |
2 |
20 |
Single-center,
randomized, vehicle-controlled, blinded, exploratory study |
| Plaque Psoriasis |
3b |
300 |
Multi-center, open-label
study |
| Plaque Psoriasis |
1 |
10 |
Single-dose, two-way
crossover |
| Pressure Ulcers |
1 |
25 |
Randomized,
blinded-assessor, controlled study |
| Pressure Ulcers |
1 |
10 |
Open-label safety study |
| Psoriasis |
1 |
40 |
Randomized,
double-blind, placebo-controlled, within subject, ascending dose
study |
| Psoriasis |
3b |
200 |
Multi-center,
randomized, double-blind, placebo-controlled study |
